UY33258A - Proteinas de union a antigeno - Google Patents

Proteinas de union a antigeno

Info

Publication number
UY33258A
UY33258A UY0001033258A UY33258A UY33258A UY 33258 A UY33258 A UY 33258A UY 0001033258 A UY0001033258 A UY 0001033258A UY 33258 A UY33258 A UY 33258A UY 33258 A UY33258 A UY 33258A
Authority
UY
Uruguay
Prior art keywords
antigen
binding proteins
proteins
union
relates
Prior art date
Application number
UY0001033258A
Other languages
English (en)
Inventor
Germaschewski Volker
Tejinder Kaur Bhinder
Susannah Karen Ford
Alan Peter Lewis
Mark Brian Pepys
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43881068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33258(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY33258A publication Critical patent/UY33258A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a proteínas de unión a antígeno, tales como anticuerpos, que se unen al componente amiloide sérico P (SAP), a polinucleótidos que codifican dichas proteínas de unión a antígeno, a composiciones farmacéuticas que comprenden dichas proteínas de unión a antígeno y a procedimientos de fabricación. La presente invención también se refiere al uso de dichas proteínas de unión a antígeno en el tratamiento o profilaxis de enfermedades asociadas con disposición amiliode que incluyen amiliodes sistémica, amiloides local, enfermesas de Alzheimer y diabetes de tipo 2.
UY0001033258A 2010-03-03 2011-03-03 Proteinas de union a antigeno UY33258A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30995710P 2010-03-03 2010-03-03

Publications (1)

Publication Number Publication Date
UY33258A true UY33258A (es) 2011-09-30

Family

ID=43881068

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033258A UY33258A (es) 2010-03-03 2011-03-03 Proteinas de union a antigeno

Country Status (39)

Country Link
EP (2) EP3025729B1 (es)
JP (2) JP5922592B2 (es)
KR (1) KR101817265B1 (es)
CN (1) CN102858371B (es)
AR (1) AR080432A1 (es)
AU (1) AU2011223048C1 (es)
BR (1) BR112012021926A2 (es)
CA (1) CA2789557A1 (es)
CL (1) CL2012002418A1 (es)
CO (1) CO6602134A2 (es)
CR (1) CR20120491A (es)
CY (2) CY1118046T1 (es)
DK (2) DK2542261T3 (es)
DO (1) DOP2012000232A (es)
EA (1) EA026375B1 (es)
ES (2) ES2593454T3 (es)
HK (2) HK1173959A1 (es)
HR (2) HRP20161096T1 (es)
HU (1) HUE028960T2 (es)
IL (2) IL221418A (es)
JO (1) JO3188B1 (es)
LT (2) LT3025729T (es)
MA (1) MA34135B1 (es)
ME (1) ME02491B (es)
MX (1) MX340350B (es)
MY (1) MY159255A (es)
NZ (1) NZ601763A (es)
PE (1) PE20130040A1 (es)
PL (2) PL3025729T3 (es)
PT (2) PT2542261T (es)
RS (2) RS57708B1 (es)
SG (2) SG183316A1 (es)
SI (2) SI3025729T1 (es)
SM (1) SMT201600337B (es)
TW (1) TWI558409B (es)
UA (1) UA108227C2 (es)
UY (1) UY33258A (es)
WO (1) WO2011107480A1 (es)
ZA (1) ZA201206529B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102753194B (zh) * 2009-12-02 2015-07-08 伊麦吉纳博公司 靶向人前列腺特异性膜抗原的j591微抗体和双抗体
CN107880126B (zh) * 2012-12-21 2021-03-30 西雅图基因公司 抗ntb-a抗体及相关组合物和方法
CN103239713A (zh) * 2013-05-28 2013-08-14 东南大学 一种糖尿病肾病微炎症小鼠模型的建立方法
GB201407506D0 (en) 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound
US9737505B2 (en) * 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
EP4137158A1 (en) 2015-08-07 2023-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
WO2019185502A1 (en) 2018-03-26 2019-10-03 Glaxosmithkline Intellectual Property Development Limited Antibodies comprising methionine sulfoxide at the ch2-ch3 interface

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methoden zur Herstellung humanisierter Antikörper
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
ES2108460T3 (es) 1993-06-03 1997-12-16 Therapeutic Antibodies Inc Fragmentos de anticuerpos en terapeutica.
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU743616B2 (en) 1997-02-07 2002-01-31 Merck & Co., Inc. Synthetic HIV gag genes
SI0915088T1 (en) * 1997-10-31 2002-12-31 F. Hoffmann-La Roche Ag D-proline derivatives
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US6903129B2 (en) 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
KR100960560B1 (ko) 2002-09-27 2010-06-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
DE60336347D1 (de) 2002-12-23 2011-04-21 Univ Rice William M Verfahren und verbindungen zur unterdrückung der fibrocyten-differenzierung
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
WO2004099173A1 (en) 2003-05-12 2004-11-18 Theracarb Inc. Multivalent inhibitors of serum amyloid p component
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
WO2009155962A1 (en) * 2008-06-27 2009-12-30 Pentraxin Therapeutics Limited Use
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use

Also Published As

Publication number Publication date
PL2542261T3 (pl) 2016-12-30
SI2542261T1 (sl) 2016-11-30
IL251031A0 (en) 2017-04-30
SMT201600337B (it) 2016-11-10
CA2789557A1 (en) 2011-09-09
EP3025729B1 (en) 2018-09-12
CY1118046T1 (el) 2017-05-17
MX2012010129A (es) 2012-09-12
CY1120803T1 (el) 2019-12-11
JP2013521252A (ja) 2013-06-10
IL221418A (en) 2017-03-30
KR101817265B1 (ko) 2018-01-10
BR112012021926A2 (pt) 2020-08-25
RS55133B1 (sr) 2016-12-30
DK2542261T3 (en) 2016-09-19
PE20130040A1 (es) 2013-02-09
MX340350B (es) 2016-07-06
SG183316A1 (en) 2012-09-27
HUE028960T2 (en) 2017-01-30
JO3188B1 (ar) 2018-03-08
MA34135B1 (fr) 2013-04-03
LT3025729T (lt) 2018-12-10
AU2011223048C1 (en) 2018-06-21
PT2542261T (pt) 2016-09-27
DOP2012000232A (es) 2013-01-15
JP2016154535A (ja) 2016-09-01
JP6236478B2 (ja) 2017-11-22
AU2011223048B2 (en) 2013-12-19
NZ601763A (en) 2014-08-29
ME02491B (me) 2017-02-20
EA201290671A1 (ru) 2013-05-30
EP3025729A1 (en) 2016-06-01
EA026375B1 (ru) 2017-04-28
HRP20161096T1 (hr) 2016-11-04
EP2542261B1 (en) 2016-07-06
SI3025729T1 (sl) 2018-11-30
AU2011223048A1 (en) 2012-10-04
PL3025729T3 (pl) 2019-02-28
RS57708B1 (sr) 2018-12-31
ZA201206529B (en) 2018-12-19
PT3025729T (pt) 2018-11-30
CN102858371B (zh) 2017-03-01
KR20130027483A (ko) 2013-03-15
TWI558409B (zh) 2016-11-21
WO2011107480A1 (en) 2011-09-09
DK3025729T3 (en) 2018-11-26
ES2593454T3 (es) 2016-12-09
IL251031A (en) 2017-11-30
CR20120491A (es) 2013-02-20
CN102858371A (zh) 2013-01-02
JP5922592B2 (ja) 2016-05-24
AR080432A1 (es) 2012-04-11
ES2699078T3 (es) 2019-02-07
EP2542261A1 (en) 2013-01-09
CO6602134A2 (es) 2013-01-18
MY159255A (en) 2016-12-30
TW201143789A (en) 2011-12-16
LT2542261T (lt) 2016-09-26
CL2012002418A1 (es) 2013-03-08
HRP20181666T1 (hr) 2018-12-14
HK1223292A1 (zh) 2017-07-28
UA108227C2 (xx) 2015-04-10
IL221418A0 (en) 2012-10-31
HK1173959A1 (zh) 2013-05-31
SG10201500382SA (en) 2015-03-30

Similar Documents

Publication Publication Date Title
UY33258A (es) Proteinas de union a antigeno
ECSP13012609A (es) Composición farmacéutica
CY1122987T1 (el) Αντισωματα εναντι αμυλοειδους βητα
AR092779A1 (es) Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
UY32341A (es) Proteínas de unión antígeno novedosas
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
CR20190445A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
CL2015001314A1 (es) Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; y uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada (div. sol. n° 679-14).
AR092818A1 (es) Anticuerpo tau humanizado
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
UA116772C2 (uk) Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47
EA201391761A1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
CL2012002896A1 (es) Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva.
WO2014031694A3 (en) Anti-tau antibodies and methods of making and using in treatment of tauopathies
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
MY164579A (en) Safe and functional humanized antibodies
EA201500261A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
BR112015004875A2 (pt) formulações de anticorpo e seus usos
BR112013000842A2 (pt) composições farmacêuticas, método de tratamento de condição de etiologia funcional do trato gastrointestinal e uso de forma potenciada ativada de anticorpo para a proteína s-100, de forma potenciada ativada de anticorpo para histamina e de forma potenciada ativada de anticorpo para a tnf-alfa.
NZ602548A (en) Oligomer-specific amyloid beta epitope and antibodies
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191217